GN
GNMLF.US Genomma Lab Internacional S.A.B. de C.V
- Market cap
- USD 831M
- P/E
- 8.5x
- P/B
- 1.27x
- ROE
- 14.6%
- Dividend yield
- 5.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GNMLF.US undervalued?
Graham numberGNMLF.US trades 30.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genomma Lab Internacional S.A.B. de C.V fundamental analysis
No fundamental analysis for Genomma Lab Internacional S.A.B. de C.V yet.
Genomma Lab Internacional S.A.B. de C.V stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the re…
Full company profileGenomma Lab Internacional S.A.B. de C.V financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genomma Lab Internacional S.A.B. de C.V annual financial statements (MXN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.3B | 12.2B | 11.8B | 13.0B | 13.9B | 15.5B | 16.9B | 16.8B | 18.6B | 17.5B | 17.1B |
| Gross Profit | 7.65B | 8.16B | 7.71B | 8.15B | 8.58B | 9.56B | 10.2B | 10.3B | 11.9B | 11.0B | 10.8B |
| Operating Income | -1.67B | 2.53B | 2.30B | 2.33B | 2.93B | 2.99B | 3.32B | 3.27B | 3.91B | 3.76B | 3.40B |
| EBITDA | -1.10B | 2.60B | 2.27B | 2.28B | 2.79B | 2.92B | 3.00B | 2.89B | 4.14B | 3.61B | 3.54B |
| Net Income | -1.69B | 1.30B | 1.11B | 783M | 1.40B | 1.31B | 1.40B | 1.11B | 1.49B | 1.61B | 1.80B |
| EPS | -1.72 | 1.36 | 1.09 | 0.77 | 1.39 | 1.30 | 1.41 | 1.16 | 1.53 | 1.66 | 1.78 |
| Balance Sheet | |||||||||||
| Total Assets | 15.8B | 16.1B | 18.1B | 19.7B | 21.3B | 21.5B | 21.7B | 21.1B | 23.0B | 23.8B | 25.5B |
| Total Liabilities | 8.97B | 8.96B | 10.7B | 11.6B | 12.5B | 11.5B | 11.5B | 11.5B | 12.1B | 12.7B | 13.2B |
| Shareholders' Equity | 6.58B | 6.94B | 7.45B | 8.17B | 8.83B | 10.1B | 10.2B | 9.56B | 10.9B | 11.1B | 12.3B |
| Cash & Short-term Investments | 1.82B | 1.11B | 1.42B | 945M | 2.05B | 1.22B | 1.51B | 1.70B | 2.38B | 2.86B | 2.76B |
| Total Debt | 5.83B | 4.77B | 5.89B | 6.25B | 6.47B | 5.96B | 6.48B | 108B | 6.49B | 7.65B | 8.12B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.36B | 1.39B | 1.04B | 1.01B | 1.71B | 1.47B | 2.05B | 2.25B | 3.03B | 1.39B | 525M |
| Capital Expenditure | 113M | 316M | 1.52B | 898M | 704M | 836M | 425M | 243M | 13.0M | 547M | 345M |
| Free Cash Flow | 1.25B | 688M | -474M | -488M | 605M | 278M | 1.25B | 1.38B | 96.4M | 838M | 180M |
| Ratios | |||||||||||
| ROE | -25.7% | 18.7% | 14.9% | 9.6% | 15.9% | 13.0% | 13.7% | 11.6% | 13.7% | 14.5% | 14.6% |
| ROA | -10.7% | 8.1% | 6.1% | 4.0% | 6.6% | 6.1% | 6.4% | 5.3% | 6.5% | 6.8% | 7.1% |
| Net Profit Margin | -14.9% | 10.6% | 9.4% | 6.0% | 10.1% | 8.4% | 8.3% | 6.6% | 8.0% | 9.2% | 10.6% |
| Debt to Equity | 0.89x | 0.69x | 0.79x | 0.76x | 0.73x | 0.59x | 0.63x | 11.29x | 0.60x | 0.69x | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genomma Lab Internacional S.A.B. de C.V dividends
- Dividend yield
- 5.21%
- Forward dividend
- 0.04 USD
- Payout ratio
- 48.4%
- Ex-dividend date
- Sep 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | MXN 781M | 0.80 | 48.4% |
| 2024 | MXN 779M | 0.80 | 52.2% |
| 2023 | USD 592M | 0.62 | 53.5% |
| 2022 | USD 782M | 0.79 | 56.0% |
| 2021 | USD 391M | 0.39 | 30.0% |
| 2020 | USD 3.73M | 0.00 | 0.3% |
| 2019 | USD 392M | 0.39 | 50.0% |
| 2018 | USD 392M | 0.38 | 35.2% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 3, 2010.
Who owns Genomma Lab Internacional S.A.B. de C.V
- Insiders 31.05%
- Institutions 31.54%
- Public & others 37.41%
- Shares outstanding 978M
- Free float 671M
Genomma Lab Internacional S.A.B. de C.V company profile
- Company name
- Genomma Lab Internacional S.A.B. de C.V
- Ticker
- GNMLF.US
- ISIN
- MX01LA010006
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,801
- Fiscal year end
- December
- Address
- Avenida Antonio Dovalí Jaime No. 70, Mexico City, DF, Mexico, 01210
- Phone
- 52 55 5081 0000
- Website
- genommalab.com
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
Genomma Lab Internacional S.A.B. de C.V management
7- Lic. Rodrigo Alonso Herrera AspraFounder & Chairman of the Board
- Mr. Juan Marco SparvieriChief Executive Officer
- Engineer Antonio Zamora GallandExecutive VP of Finance & Administration and CFO
- Ms. Christianne Ibáñez GarciaHead of Investor Relations
- Mr. Efraan Tapia CardovaDirector of Legal & Secretary
- Mr. Alejandro Bastón PatiñoEVP of Institutional Relations, Media, HR & Sustainability
- Daniel Suarez NeriaInvestor Relations Officer